Experimental and theoretical studies on structural changes in the microtubule affinity-regulating kinase 4 (MARK4) protein induced by N-hetarenes: a new class of therapeutic candidates for Alzheimer’s disease
We demonstrated that 4-(6-(arylpyrimidin-4-yl)piperazine-1-carboximidamides) are a promising class of <i>N</i>-hetarenes for developing next-generation anti-AD drugs. The reported class of compounds inhibited MARK4 activity in-vitro at micromolar concentration by targeting the ATP-binding pocket. These findings provide valuable insights for future drug design.
Authors
- Ashanul Haque (ORCID: https://orcid.org/0000-0002-6780-632X)
- Khalaf M. Alenezi (ORCID: https://orcid.org/0000-0002-8482-2110)
- Shahzaib Ahamad (ORCID: https://orcid.org/0000-0003-2009-7367)
- Dinesh Gupta (ORCID: https://orcid.org/0000-0002-7548-8835)
- Md. Ataur Rahman (ORCID: https://orcid.org/0000-0002-1247-3310)
- Saleha Anwar
- Mohd. Saeed Maulana Abdul Rasheed
Institutions
- New York University Abu Dhabi (AE)
- University of Ha'il (SA)
- International Centre for Genetic Engineering and Biotechnology (IN)
- Jamia Millia Islamia (IN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2025-03-19
- DOI
- https://doi.org/10.3389/fmed.2025.1529845
- Citations
- 1
- Primary Topic
- Computational Drug Discovery Methods
- Type
- article
- Field-Weighted Citation Impact
- 1.50